Posted by Michael Wonder on 03 Dec 2022
EQRx announces acceptance of marketing authorisation application by the European Medicines Agency for aumolertinib in EGFR mutated non-small-cell lung cancer
2 December 2022 - Application is based on data from the pivotal Phase 3 AENEAS trial evaluating aumolertinib as first-line treatment of patients with EGFR mutated non-small-cell lung cancer.
EQRx today announced that the EMA has accepted for review its marketing authorisation application for aumolertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor in development for the first-line treatment of adult patients with locally advanced or metastatic non-small-cell lung cancer with activating EGFR mutations, and for adult patients with locally advanced or metastatic EGFR T790M mutation positive non-small-cell ling cancer.
